In vivo transcriptomic profiling using cell encapsulation identifieseffector pathways of systemic aging
- Nestlé Research, Switzerland
- Université de Sherbrooke, Canada
- Centro Nacional de Investigaciones Cardiovasculares, Spain
- Pompeu Fabra University, Spain
Abstract
Sustained exposure to a young systemic environment rejuvenates aged organisms and promotes cellular function. However, due to the intrinsic complexity of tissues it remains challenging to pinpoint niche-independent effects of circulating factors on specific cell populations. Here we describe a method for the encapsulation of human and mouse skeletal muscle progenitors in diffusible polyethersulfone hollow fiber capsules that can be used to profile systemic aging in vivo independent of heterogeneous short-range tissue interactions. We observed that circulating long-range signaling factors in the old systemic environment lead to an activation of Myc and E2F transcription factors, induce senescence and suppress myogenic differentiation. Importantly, in vitro profiling using young and old serum in 2D culture does not capture all pathways deregulated in encapsulated cells in aged mice. Thus, in vivo transcriptomic profiling using cell encapsulation allows for the characterization of effector pathways of systemic aging with unparalleled accuracy.
Data availability
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (GEO). GEO Series accession numbers are GSE111401, GSE81096 and GSE193665.
-
In Vivo Transcriptomic Profiling using Cell Encapsulation Identifies Effector Pathways of Systemic AgingNCBI Gene Expression Omnibus, GSE111401.
-
In Vivo Transcriptomic Profiling using Cell Encapsulation Identifies Effector Pathways of Systemic AgingNCBI Gene Expression Omnibus, GSE193665.
Article and author information
Author details
C Florian Bentzinger
Funding
Canadian Institutes of Health Research (PJT-162442)
- C Florian Bentzinger
Association Française contre les Myopathies (AFM)
- Pura Muñoz-Cánoves
MWRF (MWRF)
- Pura Muñoz-Cánoves
Maria de Maeztu Unit of Excellence award to UPF (MDM-2014-0370)
- Pura Muñoz-Cánoves
Severo Ochoa Center of Excellence award to the CNIC (SEV-2015-0505)
- Pura Muñoz-Cánoves
Severo Ochoa FPI predoctoral fellowship (SEV-2015-0505-17-1))
- Xiaotong Hong
National Science and Research Council of Canada (RGPIN-2017-05490)
- C Florian Bentzinger
Fonds de Recherche du Québec - Santé (Dossiers 296357,34813,and 36789)
- C Florian Bentzinger
Centre de Recherche Médicale de l'Université de Sherbrooke (CRMUS Chair)
- C Florian Bentzinger
European Research Council (ERC-2016-AdG-741966)
- Pura Muñoz-Cánoves
La Caixa Foundation (La Caixa-HEALTH-HR17-00040)
- Pura Muñoz-Cánoves
Muscular Dystrophy Association (MDA)
- Pura Muñoz-Cánoves
H2020 (UPGRADE-H2020-825825)
- Pura Muñoz-Cánoves
Programa Estatal de Investigacion (RTI2018-096068-B-I00)
- Pura Muñoz-Cánoves
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: This study was performed in accordance with the Swiss regulation on animal experimentation and the European Community Council directive (86/609/EEC) for the care and use of laboratory animals. Experiments were approved by the Vaud cantonal authorities under license VD3085, and by the Animal Care and Ethics Committee of the Spanish National Cardiovascular Research Center (CNIC) and regional authorities.
Copyright
© 2022, Mashinchian et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,261
- views
-
- 340
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Further reading
-
- Cell Biology
Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.
-
- Cell Biology
- Developmental Biology
A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.
